Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
 |
|
as soon as is submitted to ZB.
Immune preventive approaches for type-1-diabetes.
Med. Monatsschr. Pharm. 41, 105-109 (2018)
Type-1-diabetes is one of the most common chronic diseases of childhood. Children with type-1-diabetes need life-long insulin treatment, with enormous consequences for the child and its family. Years to months before clinical symptoms of type-1-diabetes onset appear, subclinical destruction of the insulin producing beta cells takes place. This process is identified by circulating islet autoantibodies to beta cell antigens, and is mediated by a lack of immunological tolerance [20]. Several immune preventive approaches could already show that administration of the antigen insulin delays type-1-diabetes onset by involving the induction of insulin-specific regulatory T cells [5, 7] . Antigen-specific therapy with insulin before or immediately after the development of autoantibodies may induce the protective immune response that prevents the emergence of autoimmunity and type-1-diabetes.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
ISSN (print) / ISBN
0342-9601
Quellenangaben
Volume: 41,
Issue: 3,
Pages: 105-109
Publisher
Dt. Apotheker Verl.
Publishing Place
Stuttgart
Non-patent literature
Publications
Institute(s)
Institute of Diabetes Research Type 1 (IDF)